Market Research Reports

Companion Diagnostics Market (Breast Cancer, Lung Cancer, Colorectal Cancer, Gastric Cancer, Melanoma and Others) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019

89pages
Published Date: 2013-08-29
 

Description



Companion diagnostics refer to tests or procedures which help physicians in making improved treatment decisions regarding patients depending on their response to ongoing treatments. The rising demand for personalized medicine has largely driven the global companion diagnostics market. The market research report offers apt insights on the industry, tracking its growth, development and success during the forecast period of 2013 to 2019. 

The scope and dynamics of the market are covered in the report and the overall industry is segmented on the basis of tests for various indications and geographical location. Potential growth opportunities, emerging sectors, market drivers, challenges, landmarks, trends, government regulations and competitive landscape are also highlighted in the research report. 

In addition, the study discusses the value chain as well as Porter’s five forces analysis, highlighting the impact of suppliers, buyers, substitutes, new entrants and competitors on the global market.

Overview of the companion diagnostics market

The worldwide market for companion diagnostics was worth $1.8 billion in 2012 and is expected to reach $5.6 billion by 2019, growing at a compound annual growth rate (CAGR) of 18.1% during the period. 

The mounting R&D efforts in the field of diagnostics, advances in technologies, increasing focus on targeted therapies, and the constant attempts on the part of pharmaceutical manufacturers to lower the cost of drugs development has greatly benefited the industry. Moreover, favorable regularity changes on the part of governments, and the focus of pharmaceutical companies on in-house development of companion diagnostics or collaborating with diagnostics firms for the same are expected to further propel the market.

On the other hand, the factors which hamper the growth, as identified by the research report, are unfavorable reimbursement scenario, lengthy phases of development and approval of diagnostic technologies, and the rising influence of clinical societies and advocacy groups.

The global companion diagnostics market was led by North America in 2012, contributing more than 35% of the total revenue share. The major driving forces in the North American regional markets include widening consumer base owing to rising number of cancer cases, rising awareness regarding personalized healthcare, increased affordability of expensive procedures, and high-quality medical equipment and technology available. Increasing healthcare infrastructure and greater acceptance of innovative medical procedures will boost the regional markets in Asia and Latin America.

Companies mentioned in the market research report

There are numerous established manufacturers and small players operating in the companion diagnostics market and they have been profiled in this research report. The major companies include Qiagen N.V., Roche Holdings AG, Agilent Technologies, Inc., Abbott Laboratories, Agendia N.V., Genomic Health, Inc., Life Technologies Corporation, and GE Healthcare Ltd.
 
This market research report analyzes the following geographies:
  • North America 
  • Asia Pacific 
  • Europe
  • Rest of the World 
This report gives you access to decisive data such as:
  • Market growth drivers 
  • Factors limiting market growth
  • Current market trends 
  • Market structure
  • Market projections for the coming years 
Key highlights of this report
  • Overview of key market forces propelling and restraining market growth 
  • Up-to-date analyses of market trends and technological improvements in the micro servers industry
  • Pin-point analyses of market competition dynamics to offer you a competitive edge
  • An analysis of strategies of major competitors 
  • An array of graphics and SWOT analysis of major industry segments 
  • Detailed analyses of industry trends
  • A well-defined technological growth map with an impact-analysis 
  • Offers a clear understanding of the competitive landscape and key product segments

Table of Contents


Table of contents

Chapter 1 Introduction
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology
1.4 List of Abbreviations

Chapter 2 Executive Summary

Chapter 3 Market Overview
3.1 Introduction
3.2 Market Drivers
      3.2.1 Regulatory changes: The need for development of CDx along with targeted therapies
      3.2.2 Increasing demand as well as developmental efforts towards personalized medicine
      3.2.3 The pharmacoeconomic advantage: Reduced drug development costs
      3.2.4 Increasing cancer incidence worldwide
      3.2.5 Impact Analysis of Market Drivers
3.3 Market Restraints
      3.3.1 Effect of influence of advocacy groups and clinical societies
      3.3.2 Prolonged developmental and approval phases
      3.3.3 Reimbursement scenario
      3.3.4 Impact Analysis of Market Restraints
3.4 Market Opportunity
      3.4.1 Expansion into newer indication areas
3.5 Porter’s Five Forces Analysis: Global Companion Diagnostics Market
      3.5.1 Bargaining Power of Suppliers
      3.5.2 Bargaining Power of Buyers
      3.5.3 Threat of Substitutes
      3.5.4 Threat of New Entrants
      3.5.5 Competitive Rivalry
3.6 Market Attractiveness Analysis: Global Companion Diagnostics Market, by Geography, 2012

Chapter 4 Companion Diagnostics Market, by Indication, 2011 - 2019 (USD Million)
4.1 Introduction
      4.1.1 Comparative Analysis: Global Companion Diagnostics Market, by Indication, 2012 & 2019 (Value %)
      4.1.2 Breast Cancer
               4.1.2.1 Global Breast Cancer Companion Diagnostics Market, Size and Forecast, 2011 - 2019 (USD Million)
      4.1.3 Lung Cancer
              4.1.3.1 Global Lung Cancer Companion Diagnostics Market, Size and Forecast, 2011 - 2019 (USD Million)
      4.1.4 Colorectal Cancer
               4.1.4.1 Global Colorectal Cancer Companion Diagnostics Market, Size and Forecast, 2011 - 2019 (USD Million)
      4.1.5 Gastric Cancer
               4.1.5.1 Global Gastric Cancer Companion Diagnostics Market, Size and Forecast, 2011 - 2019 (USD Million)
      4.1.6 Melanoma
              4.1.6.1 Global Melanoma Companion Diagnostics Market, Size and Forecast, 2011 - 2019 (USD Million)
      4.1.7 Others (HIV, Thalassemia)
               4.1.7.1 Global Other Companion Diagnostics Market, Size and Forecast, 2011 - 2019 (USD Million)

Chapter 5 Companion Diagnostics Market, by Geography, 2011 - 2019 (USD Million)
5.1 Overview
      5.1.1 Comparative Analysis: Global Companion Diagnostics Market by Geography, 2012 & 2019 (Value %)
5.2 North America
      5.2.1 North America Companion Diagnostics Market, Size and Forecast, 2011 - 2019 (USD Million)
5.3 Europe
      5.3.1 Europe Companion Diagnostics Market, Size and Forecast, 2011 - 2019 (USD Million)
5.4 Asia-Pacific
      5.4.1 Asia-Pacific Companion Diagnostics Market, Size and Forecast, 2011 - 2019 (USD Million)
5.5 Rest of the World (RoW)
      5.5.1 RoW Companion Diagnostics Market, Size and Forecast 2011 - 2019  (USD Million)

Chapter 6 Competitive Landscape
6.1 Market Share by Key Players, 2012 (%)

Chapter 7 Recommendations
7.1 Adoption of newer business models enabling co-developing companion diagnostics
7.2 Focus on research-intense investments

Chapter 8 Company Profiles
8.1 Abbott Laboratories
      8.1.1 Company Overview
      8.1.2 Financial Overview
      8.1.3 Product Portfolio
      8.1.4 Business Strategies
      8.1.5 Recent Developments
               8.1.5.1 FDA Approval
8.2 Agendia N.V.
      8.2.1 Company Overview
      8.2.2 Product Portfolio
      8.2.3 Business Strategies
      8.2.4 Recent Developments
8.3 Agilent Technologies, Inc.
      8.3.1 Company Overview
      8.3.2 Financial Overview
      8.3.3 Product Portfolio
      8.3.4 Business Strategies
      8.3.5 Recent Developments
8.4 BioGenex Laboratories Inc.
      8.4.1 Company Overview
      8.4.2 Product Portfolio
      8.4.3 Business Strategies
      8.4.4 Recent Developments
8.5 bioMérieux SA
      8.5.1 Company Overview
      8.5.2 Financial Overview
      8.5.3 Product Portfolio
      8.5.4 Business Strategies
      8.5.5 Recent Developments
8.6 GE Healthcare Ltd.
      8.6.1 Company Overview
      8.6.2 Financial Overview
      8.6.3 Product Portfolio
      8.6.4 Business Strategies
      8.6.5 Recent Developments
8.7 Genomic Health, Inc.
      8.7.1 Company Overview
      8.7.2 Financial Overview
      8.7.3 Product Portfolio
      8.7.4 Business Strategies
      8.7.5 Recent Developments
8.8 Life Technologies Corporation
      8.8.1 Company Overview
      8.8.2 Financial Overview
      8.8.3 Product Portfolio
      8.8.4 Business Strategies
      8.8.5 Recent Developments
8.9 Qiagen N.V.
      8.9.1 Company Overview
      8.9.2 Financial Overview
      8.9.3 Product Portfolio
      8.9.4 Business Strategies
      8.9.5 Recent Developments
8.10 Resonance Health Analysis Services Pty Ltd.
      8.10.1 Company Overview
      8.10.2 Product Portfolio
      8.10.3 Business Strategies
      8.10.4 Recent Developments
8.11 Roche Holdings AG
      8.11.1 Company Overview
      8.11.2 Financial Overview
      8.11.3 Product Portfolio
      8.11.4 Business Strategies
      8.11.5 Recent Developments
8.12 Siemens Healthcare
      8.12.1 Company Overview
      8.12.2 Financial Overview
      8.12.3 Product Portfolio
      8.12.4 Business Strategies 
      8.12.5 Recent Developments

List of Figures

FIG. 1 Companion Diagnostics Market Segmentation
FIG. 2 Global Companion Diagnostics Market, by Indication, 2012 (USD Million)
FIG. 3 Porter’s Five Forces Analysis: Global Companion Diagnostics Market
FIG. 4 Market Attractiveness Analysis: Global Companion Diagnostics Market, by Geography, 2012
FIG. 5 Comparative Analysis: Global Companion Diagnostics Market, by Indication, 2012 & 2019 (Value %)
FIG. 6 Global Breast Cancer Companion Diagnostics Market, Size and Forecast, 2011 - 2019 (USD Million)
FIG. 7 Global Lung Cancer Companion Diagnostics Market, Size and Forecast, 2011 - 2019 (USD Million)
FIG. 8 Global Colorectal Cancer Companion Diagnostics Market, Size and Forecast, 2011 - 2019 (USD Million)
FIG. 9 Global Gastric Cancer Companion Diagnostics Market, Size and Forecast, 2011 - 2019 (USD Million)
FIG. 10 Global Melanoma Companion Diagnostics Market, Size and Forecast, 2011 - 2019 (USD Million)
FIG. 11 Global Other Companion Diagnostics Market, Size and Forecast, 2011 - 2019 (USD Million)
FIG. 12 Comparative Analysis: Global Companion Diagnostics Market, by Geography, 2012 & 2019 (Value %)
FIG. 13 North America Companion Diagnostics Market, Size and Forecast, 2011 – 2019 (USD Million)
FIG. 14 Europe Companion Diagnostics Market, Size and Forecast, 2011 – 2019 (USD Million)
FIG. 15 Asia-Pacific Companion Diagnostics Market, Size and Forecast, 2011 – 2019 (USD Million)
FIG. 16 RoW Companion Diagnostics Market, Size and Forecast, 2011 - 2019 (USD Million)
FIG. 17 Market Share Analysis: Global Companion Diagnostics Market, 2012 (%)
FIG. 18 Annual Revenues: Abbott Laboratories, 2010 – 2012 (USD Million)
FIG. 19 Annual Revenue: Agilent Technologies, Inc., 2010 – 2012 (USD Million)
FIG. 20 Annual Revenues:  bioMérieux SA, 2010 – 2012 (USD Million)
FIG. 21 Annual Revenue: GE Healthcare Ltd., 2010 – 2012 (USD Million)
FIG. 22 Annual Revenues: Genomic Health Inc.,  2010 – 2012 (USD Million)
FIG. 23 Annual Revenues: Life Technologies Corporation, 2010 – 2012 (USD Million)
FIG. 24 Annual Sales: Qiagen N.V., 2010 – 2012 (USD Million)
FIG. 25 Annual Revenues: Roche Holdings AG, 2010 – 2012 (USD Million) (1 CHF = 1.09 USD)
FIG. 26 Annual Revenues: Siemens Healthcare, 2010 – 2012 (USD Million)

List of Tables

TABLE 1 List of Abbreviations
TABLE 2 Market Snapshot: Global Companion Diagnostics Market
TABLE 3 Cancer Incidence, by Type, 2008 and 2015 (Million)
TABLE 4 Impact Analysis of Market Drivers
TABLE 5 Impact Analysis of Market Restraints
TABLE 6 Companion Diagnostics Required or Recommended by the U.S. FDA
TABLE 7 Global Companion Diagnostics Market, by Indication, 2011 - 2019 (USD Million)
TABLE 8 Breast Cancer Companion Diagnostics (CDx), Manufacturers and Target Drugs
TABLE 9 Lung Cancer Companion Diagnostics (CDx), Manufacturers and Target Drugs
TABLE 10 Colorectal Cancer Companion Diagnostics (CDx), Manufacturers and Target Drugs
TABLE 11 Gastric Cancer Companion Diagnostics (CDx), Manufacturers and Target Drugs
TABLE 12 Melanoma Companion Diagnostics (CDx), Manufacturers and Target Drugs
TABLE 13 Other Companion Diagnostics (CDx), Indications and Manufacturers
TABLE 14 Global Companion Diagnostics Market, by Geography, Size and Forecast, 2011 - 2019 (USD Million)

Enquiry Before Buying


Free Market Analysis


Companion diagnostics facilitate the enhancement of a specific drug treatment by the patient’s response at every stage of treatment. These tests specify whether the patient is likely to respond to the treatment or witness adverse reactions, and also enable optimization of dosing concentrations of the drug. The medications currently available commercially are becoming more and more personalized or targeted to specific patient populations. The development of a companion diagnostic along with the drug enables shortened drug development processes as its efficacy is already mapped by the patient outcomes. Hence, use of companion diagnostics increase the possibility of a drug attaining regulatory approval and also helps in evading long clinical trial design as only the targeted patient population needs to participate in the clinical trials.

The escalating costs involved in drug discovery and development have created a need for development of cost effective solutions. Many pharmaceutical companies are now focusing on the co-development of companion diagnostics along with the drug. This co-development strategy enables the commercialization of safer and efficient drug candidates. With the advent of personalized medicine and unfolding of human genome complexity, many pharmaceutical companies have reconsidered their current business models by moving away from ill-defined therapeutics to more specific personalized or targeted therapies.

Companion diagnostics provide insights about various issues associated with any type of drug treatment such as adverse reactions, toxicity and patient stratification. Pharmaceutical manufacturers are therefore focusing on development of tailor made therapies with the help of diagnostics manufacturers, in order to cater to the increasing demand for disease-specific therapies and defined target population. A large number of companion diagnostics are being developed in the field of oncology due to the continuous exploration of cancer-specific biomarkers, advanced technological platforms and large populations affected by different types of cancers.

Geographically, North America dominated the global companion diagnostics market in 2012 with a revenue share of over 35%. Technological advances, increased healthcare awareness, large consumer base, and better affordability for expensive diagnostic procedures are the major factors responsible for the region’s leadership position. Factors such as major focus on rigorous research and development in the field of molecular diagnostics and presence of major market players are expected to drive growth of this market during the forecast period. Furthermore, in case of the Asian and Latin American markets, factors such as increasing awareness, rising number of cancer cases, developing infrastructure facilities and increasing acceptance of consumers towards novel approaches will enhance the uptake of companion diagnostics and drive market growth. On the other hand, factors which might hamper the growth of the overall companion diagnostics market are lack of well-defined regulatory guidelines for the development of companion diagnostics, prolonged developmental and approval processes and the need for high technology-based infrastructure to ensure highly sensitive detections. 

global-companion-diagnostics-market-revenues-by-indications-2012
 

To get discount on this report, just click on the button below.

To receive brochure, please click on the button below.

Share This Market Study!  

Upcoming Report

Payment
Copyright @ Transparency Market Research